<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580564</url>
  </required_header>
  <id_info>
    <org_study_id>KL167-Ⅱ-03-CTP</org_study_id>
    <nct_id>NCT03580564</nct_id>
  </id_info>
  <brief_title>An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</brief_title>
  <official_title>An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy of BGB-A317 a in subjects with relapsed or refractory&#xD;
      classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano&#xD;
      Classification&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 30, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 2years</time_frame>
    <description>Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the first dose of KL-A167 to the date of PD or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the first dose of KL-A167 to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the date of the first dose of KL-A167 to the time the response criteria are first met</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL-A167</intervention_name>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Histopathological confirmed classical Hodgkin's lymphoma&#xD;
&#xD;
          -  Relapsed/refractory cHL include：subject with no response to or with progression after&#xD;
             ASCT ；subject which failed failed second line and above chemtherapy；subject which&#xD;
             didn't achieve PR after 2 cycles or didn't achieve CR after 4 cycles&#xD;
&#xD;
          -  At least one measurable disease (long axis&gt;15 mm and short axis&gt;5 mm,or both axis&gt;10&#xD;
             mm）&#xD;
&#xD;
          -  ECOG performance status of 0 or 12&#xD;
&#xD;
          -  Subject must have adequate organ functions and meet requirements on laboratory&#xD;
             values.：Count of Blood Cells: absolute neutrophil count (ANC) ≥ 1.0 × 109 / L;&#xD;
             platelet count (PLT) ≥ 50 × 109 / L; hemoglobin content (HGB) ≥ 7.0 g / Dl; Liver&#xD;
             function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN，with the&#xD;
             exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients&#xD;
             with hepatic metastases or Gilbert's syndrome (total bilirubin ≤ 3 × ULN)Renal&#xD;
             function: serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance rate（CCR）≥50&#xD;
             mL/min；International normalized ratio (INR) ≤ 1.5 x ULN ；Thyroid function: thyroid&#xD;
             stimulating hormone (TSH) in normal range.&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including&#xD;
             Chinese herbal medicine and Chinese patent medicine) used to control cancer including&#xD;
             locoregional treatment must have been completed ≥ 4 weeks before the first dose of&#xD;
             KL-A167(Mitomycin or nitroso must have been completed ≥ 6 weeks), and all&#xD;
             treatment-related adverse events (except alopecia) are stable and have either returned&#xD;
             to baseline or Grade 0/1&#xD;
&#xD;
          -  Subjects of reproductive potential must be willing to use adequate contraception&#xD;
             during the course of the study and through 6 months after the last dose of study&#xD;
             medication&#xD;
&#xD;
          -  Subject has voluntarily agreed to participate by giving written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.&#xD;
&#xD;
          -  Known central nervous system lymphoma.&#xD;
&#xD;
          -  Prior malignancy except for curatively treated carcinoma in situ of the cervix or&#xD;
             breast ，Superficial bladder cancer，and Squamous cell carcinoma in situ&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to monoclonal antibodies&#xD;
&#xD;
          -  Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.&#xD;
&#xD;
          -  need the other anticancer therapy during the study&#xD;
&#xD;
          -  Received any anticancer vaccine or other medications for immunomodulatory receptor&#xD;
             preparations&#xD;
&#xD;
          -  Received HSCT&#xD;
&#xD;
          -  Received ASCT in the past 3 months&#xD;
&#xD;
          -  Serious acute or chronic infection requiring systemic therapy.&#xD;
&#xD;
          -  Subject with active autoimmune disease or history of autoimmune disease with high risk&#xD;
             of recurrence.&#xD;
&#xD;
          -  Conditions requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             Prednisone equivalent) or other immunosuppressive medications within 14 days of first&#xD;
             dose of KL-A167&#xD;
&#xD;
          -  serious medical diseases, ex Suffering from heart failure (New York Heart Association&#xD;
             standard III or IV), ischemic heart disease (such as myocardial infarction or angina),&#xD;
             congestive heart failure and other cardiovascular diseases, uncontrolled&#xD;
             diabetes(fasting blood glucose≥10 mmol/L), uncontrolled high blood pressure(Systolic&gt;&#xD;
             150 mmHg and / or diastolic&gt; 100 mmHg), LVEF&lt;50%&#xD;
&#xD;
          -  QTcF&gt;450 msec&#xD;
&#xD;
          -  Known active HBV or HCV infection.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Has history of interstitial lung disease or non-infectious pneumonitis. Subjects with&#xD;
             prior drug-induced or radiation-induced pneumonitis who are asymptomatic are eligible.&#xD;
&#xD;
          -  Known active pulmonary tuberculosis&#xD;
&#xD;
          -  Has history of AE related with immune system during the Immunotherapy&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan&#xD;
             to receive live vaccine during study period.&#xD;
&#xD;
          -  Known neurological or psychiatric diseases&#xD;
&#xD;
          -  Ongoing alcohol or drug abuse&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Participation in another clinical trial within the past 4 weeks&#xD;
&#xD;
          -  Other significant disease that in the investigator's opinion should exclude the&#xD;
             subject from the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dawei Wu</last_name>
    <phone>010-87788268</phone>
    <email>wumingshi-117@163.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

